as of 12-12-2025 3:41pm EST
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 4.0B | IPO Year: | 2020 |
| Target Price: | $304.43 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.70 - $278.44 | Next Earning Date: | 11-05-2025 |
| Revenue: | $7,463,000 | Revenue Growth: | 364.98% |
| Revenue Growth (this year): | -96.42% | Revenue Growth (next year): | -73.33% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
10% Owner
Avg Cost/Share
$111.24
Shares
313,910
Total Value
$33,198,123.57
Owned After
2,361,485
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Adage Capital Management, L.P. | PRAX | 10% Owner | Oct 16, 2025 | Sell | $111.24 | 313,910 | $33,198,123.57 | 2,361,485 |
See how PRAX stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "PRAX Praxis Precision Medicines Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.